Business Daily Media

Men's Weekly

.

Eisai: Dayvigo (Lemborexant) Approved for Treatment of Insomnia in Japan

  • Written by ACN Newswire - Press Releases

image

TOKYO, Jan 23, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has obtained the manufacturing and marketing approval in Japan for its in-house discovered orexin receptor antagonist DAYVIGO (2.5mg, 5mg, and 10mg tablets, lemborexant) for treatment of insomnia.

DAYVIGO is a dual orexin receptor antagonist that inhibits orexin

Read more //?#

Refunds to Revenue: AI and loyalty perks help retailers in post-holiday hangover

Australian retailers are turning to artificial intelligence to simplify and automate returns and exchanges, while strengthening loyalty programs a...

Stop reading from the script: Why authenticity is the customer success secret weapon

I’ve been in customer service for years now. As my team has grown, the number one piece of advice I give is to be your...

From Check-in to Touchdown: How AI and smarter systems are transforming the travel industry

Richard Valente, VP of Customer Experience Strategy at TP in Australia, explores how IT-BPM outsourcing is revolutionising the travel sector throu...

Online Christmas shoppers fund climate and biodiversity projects via HealthPost's Click Sphere for Good initiative

Online shoppers with HealthPost’s Flora & Fauna have made 11,000 contributions towards climate and biodiversity projects when ordering parcel ...

US landmark settlement protects SMEs, highlighting flaws in the RBA's proposed blanket card surcharging ban for Australia

Aussie SMEs warn RBA not to ignore global trends, with the current sledgehammer approach threatening business viability and increasing inflation ...

Thryv Australia named Employer of Choice for third consecutive year at Australian Business Awards

Thryv® (NASDAQ: THRY), Australia’s provider of the leading small business marketing and sales software platform, has been awarded the Employer of ...